You are here

Copaxone®

Prof. Michael Sela
10.10.2010
from the institute to Teva Pharmaceuticals Ltd.
Prof. Ephraim Katzir
12.09.2010
In the 1950s, Prof. Ephraim Katzir developed simple synthetic models, known as polyamino acids, that...
Prof. Ephrain Katzir, 1916-2009
01.10.2009
Professor Ephraim Katzir passed away on Saturday, May 30, 2009
Prof. Ruth Arnon
01.05.2009
From student to Institute Vice President
Genes that affect reponses of MS to Copaxone
10.10.2007

Israeli scientists identify: Genes that Affect Responses of Multiple Sclerosis Patients to Copaxone®

...
Optic nerve fiber (orange) on background of neural network.
01.01.2002

One in every hundred adults in the Western world suffers from chronic glaucoma, a disease that causes blindness. Prof. Michal Schwartz,...

Prof. Michal Schwartz
01.05.2001

Institute scientists halt progressive eyesight loss in animals afflicted with a glaucoma-like disease

Scientists Block Loss Of Eyesight In Animals With A Glaucoma-Like Disease
06.03.2000
Weizmann Institute scientists have succeeded in stopping the progressive loss of eyesight in animals with a glaucoma-like disease....
Past, Present & Future Perfect
01.05.1998

Prof. Ephraim Katzir reminisces about the last 50 years of the Weizmann Institute

Cop 1 (Copaxone®): The Story of a Drug
01.05.1997

Nearly three decades after a surprising discovery, Copaxone® gets FDA approval for the treatment of MS

Pages